Comparing Rhythm Pharmaceuticals (NASDAQ:RYTM) and Scinai Immunotherapeutics (NASDAQ:SCNI)

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and profitability.

Profitability

This table compares Rhythm Pharmaceuticals and Scinai Immunotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-69.03%	-171.16%	-43.00%
Scinai Immunotherapeutics	N/A	N/A	N/A

Volatility & Risk

Rhythm Pharmaceuticals has a beta of 2.17, indicating that its stock price is 117% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.27, indicating that its stock price is 127% more volatile than the S&P 500.

Institutional & Insider Ownership

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 6.0% of Scinai Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Rhythm Pharmaceuticals and Scinai Immunotherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1	3	18	0	2.77
Scinai Immunotherapeutics	1	0	0	0	1.00

Rhythm Pharmaceuticals currently has a consensus price target of $142.00, suggesting a potential upside of 24.83%. Given Rhythm Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts clearly believe Rhythm Pharmaceuticals is more favorable than Scinai Immunotherapeutics.

Valuation and Earnings

This table compares Rhythm Pharmaceuticals and Scinai Immunotherapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76 million	41.56	-$196.54 million	($2.90)	-39.23
Scinai Immunotherapeutics	$1.31 million	0.53	-$8.31 million	($95.34)	-0.01

Scinai Immunotherapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Scinai Immunotherapeutics beats Rhythm Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.